Cosmo Pharmaceuticals NV banner

Cosmo Pharmaceuticals NV
F:C43

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
F:C43
Watchlist
Price: 87.9 EUR -0.79% Market Closed
Market Cap: €1.4B

Intrinsic Value

The intrinsic value for Cosmo Pharmaceuticals NV (C43) under the Base Case is 177.26 EUR. Compared with the current market price of 87.9 EUR, the stock appears Undervalued by 50% .

Based on two methods:

DCF suggests undervaluation, while multiples suggest overvaluation.

C43 Intrinsic Value
177.26 EUR
Undervaluation 50%
Intrinsic Value
Price €87.9
Base Case Scenario
Monitor C43
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €141.81
Get notified when the price drops into your buy zone
Intrinsic Value €177.26
Margin of Safety 20% €141.81
Current Price €87.9
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about C43?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is C43 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Cosmo Pharmaceuticals NV.

Explain Valuation
Alternatives to C43

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

COPN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one C43 stock?

The intrinsic value for Cosmo Pharmaceuticals NV (C43) under the Base Case is 177.26 EUR.

Is C43 stock undervalued or overvalued?

Compared with the current market price of 87.9 EUR, the stock appears Undervalued by 50% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett